This company is developing targeted therapies to provide solutions for patients suffering from hematological malignancies. Its platform provides treatment for both hematopoietic stem cell transplants and targeted therapies, such as antibody drug conjugates (ADCs), bispecific antibodies and CAR-T cell treatments, including CD33 CAR-T.